RSS feed

Publications (original articles or review articles) published in 2024 from OUS - Department of Gynaecological Oncology

15 publications found

Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S (2024)
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
J Immunother Cancer, 12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812

Davidson B, Holth A, Lindemann K, Zahl Eriksson AG, Nilsen TA, Torgunrud A (2024)
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03821-9, PubMed 38733380

Davidson B, Skeie-Jensen T, Holth A, Hausladen S (2024)
Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
Int J Gynecol Pathol (in press)
DOI 10.1097/PGP.0000000000001030, PubMed 38847524

Fotopoulou C, Eriksson AG, Planchamp F, Morice P, Taylor A, Sturdza A, Florin Coza O, Halaska MJ, Martinelli F, Armbrust R, Chargari C (2024)
European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management
Int J Gynecol Cancer, 34 (4), 480-489
DOI 10.1136/ijgc-2024-005293, PubMed 38395448

Lindemann K, Kildal W, Kleppe A, Tobin KAR, Pradhan M, Isaksen MX, Vlatkovic L, Danielsen HE, Kristensen GB, Askautrud HA (2024)
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
Eur J Cancer, 200, 113584
DOI 10.1016/j.ejca.2024.113584, PubMed 38330767

Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A et al. (2024)
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Lancet, 403 (10434), 1341-1350
DOI 10.1016/S0140-6736(24)00317-9, PubMed 38521086

Luijten MMW, van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Krakstad C, Witteveen PO, Galaal K, van Ginkel AA, Bignotti E, Weinberger V, Sweegers S, Eriksson AGZ, Keizer DM, van de Stolpe A, Romano A, Pijnenborg JMA, European Network For Individualized Treatment In Endometrial Cancer (2024)
Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
Cancers (Basel), 16 (11)
DOI 10.3390/cancers16112084, PubMed 38893205

Mirza MR, Tandaric L, Henriksen JR, Mäenpää J, Christensen RD, Waldstrøm M, Lindemann K, Roed H, Auranen A, Akslen LA, Thomsen LCV, Lindberg SN, Madsen K, Bjørge L (2024)
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
Gynecol Oncol, 188, 103-110 (in press)
DOI 10.1016/j.ygyno.2024.06.017, PubMed 38943691

Os SS, Skipar K, Skovlund E, Hompland I, Hellebust TP, Guren MG, Lindemann K, Nakken ES (2024)
Survival prediction in patients with gynecological cancer irradiated for brain metastases
Acta Oncol, 63, 206-212
DOI 10.2340/1651-226X.2023.34899, PubMed 38647023

Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjólfsdóttir B, Kim JW, Gleeson N, Brotto L, Tu D, Shepherd LE, CX.5 SHAPE investigators, CX.5 SHAPE Investigators (2024)
Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
N Engl J Med, 390 (9), 819-829
DOI 10.1056/NEJMoa2308900, PubMed 38416430

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911

Rostami S, Rounge TB, Pestarino L, Lyle R, Fortner RT, Haaland ØA, Lie RT, Wiklund F, Bjørge T, Langseth H (2024)
Differential levels of circulating RNAs prior to endometrial cancer diagnosis
Int J Cancer, 155 (5), 946-956
DOI 10.1002/ijc.34951, PubMed 38733362

Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
Radiother Oncol, 195, 110263
DOI 10.1016/j.radonc.2024.110263, PubMed 38556173

Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, Elias KM, Fendler W, Langseth H (2024)
Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches
Front Oncol, 14, 1389066
DOI 10.3389/fonc.2024.1389066, PubMed 38983926

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731